IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v35y2017i11d10.1007_s40273-017-0553-x.html
   My bibliography  Save this article

Replicating Health Economic Models: Firm Foundations or a House of Cards?

Author

Listed:
  • Inigo Bermejo

    (University of Sheffield)

  • Paul Tappenden

    (University of Sheffield)

  • Ji-Hee Youn

    (University of Manchester)

Abstract

Health economic evaluation is a framework for the comparative analysis of the incremental health gains and costs associated with competing decision alternatives. The process of developing health economic models is usually complex, financially expensive and time-consuming. For these reasons, model development is sometimes based on previous model-based analyses; this endeavour is usually referred to as model replication. Such model replication activity may involve the comprehensive reproduction of an existing model or ‘borrowing’ all or part of a previously developed model structure. Generally speaking, the replication of an existing model may require substantially less effort than developing a new de novo model by bypassing, or undertaking in only a perfunctory manner, certain aspects of model development such as the development of a complete conceptual model and/or comprehensive literature searching for model parameters. A further motivation for model replication may be to draw on the credibility or prestige of previous analyses that have been published and/or used to inform decision making. The acceptability and appropriateness of replicating models depends on the decision-making context: there exists a trade-off between the ‘savings’ afforded by model replication and the potential ‘costs’ associated with reduced model credibility due to the omission of certain stages of model development. This paper provides an overview of the different levels of, and motivations for, replicating health economic models, and discusses the advantages, disadvantages and caveats associated with this type of modelling activity. Irrespective of whether replicated models should be considered appropriate or not, complete replicability is generally accepted as a desirable property of health economic models, as reflected in critical appraisal checklists and good practice guidelines. To this end, the feasibility of comprehensive model replication is explored empirically across a small number of recent case studies. Recommendations are put forward for improving reporting standards to enhance comprehensive model replicability.

Suggested Citation

  • Inigo Bermejo & Paul Tappenden & Ji-Hee Youn, 2017. "Replicating Health Economic Models: Firm Foundations or a House of Cards?," PharmacoEconomics, Springer, vol. 35(11), pages 1113-1121, November.
  • Handle: RePEc:spr:pharme:v:35:y:2017:i:11:d:10.1007_s40273-017-0553-x
    DOI: 10.1007/s40273-017-0553-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-017-0553-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40273-017-0553-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Don Husereau & Michael Drummond & Stavros Petrou & Chris Carswell & David Moher & Dan Greenberg & Federico Augustovski & Andrew Briggs & Josephine Mauskopf & Elizabeth Loder, 2013. "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement," PharmacoEconomics, Springer, vol. 31(5), pages 361-367, May.
    2. Briggs, Andrew & Sculpher, Mark & Claxton, Karl, 2006. "Decision Modelling for Health Economic Evaluation," OUP Catalogue, Oxford University Press, number 9780198526629.
    3. Paul Tappenden & Shijie Ren & Rachel Archer & Rebecca Harvey & Marrissa Martyn-St James & Hasan Basarir & John Stevens & Alan Lobo & Sami Hoque, 2016. "A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy," PharmacoEconomics, Springer, vol. 34(10), pages 1023-1038, October.
    4. Maria Alva & Alastair Gray & Borislava Mihaylova & Philip Clarke, 2014. "The Effect Of Diabetes Complications On Health‐Related Quality Of Life: The Importance Of Longitudinal Data To Address Patient Heterogeneity," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 487-500, April.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Inigo Bermejo & Paul Tappenden & Ji-Hee Youn, 2017. "Response to ‘Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”’," PharmacoEconomics, Springer, vol. 35(11), pages 1189-1190, November.
    2. Emma McManus & Tracey Sach, 2017. "Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”," PharmacoEconomics, Springer, vol. 35(11), pages 1187-1188, November.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Qi Cao & Erik Buskens & Hans L. Hillege & Tiny Jaarsma & Maarten Postma & Douwe Postmus, 2019. "Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 475-482, April.
    2. Neily Zakiyah & Antoinette D I van Asselt & Frank Roijmans & Maarten J Postma, 2016. "Economic Evaluation of Family Planning Interventions in Low and Middle Income Countries; A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(12), pages 1-19, December.
    3. Paul Tappenden & James Chilcott, 2014. "Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models," PharmacoEconomics, Springer, vol. 32(10), pages 967-979, October.
    4. Maximilian Hatz & Reiner Leidl & Nichola Yates & Björn Stollenwerk, 2014. "A Systematic Review of the Quality of Economic Models Comparing Thrombosis Inhibitors in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention," PharmacoEconomics, Springer, vol. 32(4), pages 377-393, April.
    5. Manal H. El-Hamamsy & Gihan H. Elsisi & Randa Eldessouki & Mohamed M. Elmazar & Ahmed S. Taha & Basma F. Awad & Hossam Elmansy, 2016. "Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 431-440, August.
    6. David Brain & Ruth Tulleners & Xing Lee & Qinglu Cheng & Nicholas Graves & Rosana Pacella, 2019. "Cost-effectiveness analysis of an innovative model of care for chronic wounds patients," PLOS ONE, Public Library of Science, vol. 14(3), pages 1-13, March.
    7. Blythe Adamson & Dobromir Dimitrov & Beth Devine & Ruanne Barnabas, 2017. "The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 1(1), pages 1-12, March.
    8. Magnus Zingmark & Ingeborg Nilsson & Fredrik Norström & Klas Göran Sahlén & Lars Lindholm, 2017. "Cost effectiveness of an intervention focused on reducing bathing disability," European Journal of Ageing, Springer, vol. 14(3), pages 233-241, September.
    9. Simone A. Huygens & Isaac Corro Ramos & Carlijn V. C. Bouten & Jolanda Kluin & Shih Ting Chiu & Gary L. Grunkemeier & Johanna J. M. Takkenberg & Maureen P. M. H. Rutten-van Mölken, 2020. "Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(4), pages 557-572, June.
    10. Steffen Flessa & Dominik Dietz & Elisabete Weiderpass, 2016. "Health policy support under extreme uncertainty: the case of cervical cancer in Cambodia," EURO Journal on Decision Processes, Springer;EURO - The Association of European Operational Research Societies, vol. 4(3), pages 183-218, November.
    11. Ben Kearns & Roberta Ara & Allan Wailoo & Andrea Manca & Monica Alava & Keith Abrams & Mike Campbell, 2013. "Good Practice Guidelines for the use of Statistical Regression Models in Economic Evaluations," PharmacoEconomics, Springer, vol. 31(8), pages 643-652, August.
    12. Pepijn Vemer & Maureen Rutten-van Mölken, 2013. "The Road Not Taken: Transferability Issues in Multinational Trials," PharmacoEconomics, Springer, vol. 31(10), pages 863-876, October.
    13. Carmen Selva-Sevilla & Elena Conde-Montero & Manuel Gerónimo-Pardo, 2020. "Bayesian Regression Model for a Cost-Utility and Cost-Effectiveness Analysis Comparing Punch Grafting Versus Usual Care for the Treatment of Chronic Wounds," IJERPH, MDPI, vol. 17(11), pages 1-21, May.
    14. Deidda, Manuela & Geue, Claudia & Kreif, Noemi & Dundas, Ruth & McIntosh, Emma, 2019. "A framework for conducting economic evaluations alongside natural experiments," Social Science & Medicine, Elsevier, vol. 220(C), pages 353-361.
    15. Brown, Vicki & Diomedi, Belen Zapata & Moodie, Marj & Veerman, J. Lennert & Carter, Rob, 2016. "A systematic review of economic analyses of active transport interventions that include physical activity benefits," Transport Policy, Elsevier, vol. 45(C), pages 190-208.
    16. David Brain & Jonathan Mitchell & James O’Beirne, 2020. "Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care," PLOS ONE, Public Library of Science, vol. 15(6), pages 1-13, June.
    17. Inigo Bermejo & Paul Tappenden & Ji-Hee Youn, 2017. "Response to ‘Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”’," PharmacoEconomics, Springer, vol. 35(11), pages 1189-1190, November.
    18. Carmen Selva-Sevilla & F Dámaso Fernández-Ginés & Manuel Cortiñas-Sáenz & Manuel Gerónimo-Pardo, 2021. "Cost-effectiveness analysis of domiciliary topical sevoflurane for painful leg ulcers," PLOS ONE, Public Library of Science, vol. 16(9), pages 1-18, September.
    19. Gerardus Frederix & Hossein Haji Ali Afzali & Erik Dasbach & Robyn Ward, 2015. "Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions," PharmacoEconomics, Springer, vol. 33(8), pages 777-781, August.
    20. Sarah J Iribarren & Kenrick Cato & Louise Falzon & Patricia W Stone, 2017. "What is the economic evidence for mHealth? A systematic review of economic evaluations of mHealth solutions," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-20, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:35:y:2017:i:11:d:10.1007_s40273-017-0553-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.